Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) will report its first quarter financial results on May 5, 2022, followed by a corporate update and a conference call at 5:00 p.m. ET. The company specializes in cortisol modulation and has developed a portfolio of proprietary compounds for serious disorders, including Cushing's syndrome. Korlym®, its flagship drug, was the first FDA-approved treatment for Cushing's. Details for joining the call are provided, ensuring access for investors and stakeholders.

Positive

• Corcept's drug Korlym® is the first FDA-approved treatment for Cushing's syndrome.
• The company has a strong portfolio of proprietary compounds aimed at various serious disorders.

Negative

• None.

MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.

Click to Join Meeting

Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 6942208.

A replay will be available through May 12, 2022, at 1-855-859-2056 from the United States and 1-404-537-3406 internationally. The passcode will be 6942208. You may also access a replay on the Investors / Past Events tab of www.corcept.com

About Corcept Therapeutics

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators as potential treatments for patients with Cushing’s syndrome, ovarian, adrenal and prostate cancer, weight gain caused by the use of antipsychotic medications and liver disease. Corcept’s drug Korlym^® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.

CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com

FAQ

When will Corcept Therapeutics report its first quarter financial results?

Corcept Therapeutics will report its first quarter financial results on May 5, 2022.

What is the significance of Korlym® for Corcept Therapeutics?

Korlym® is the first FDA-approved medication for the treatment of Cushing's syndrome, indicating Corcept's innovation in cortisol modulation.

What time is the Corcept Therapeutics conference call?

The conference call is scheduled for May 5, 2022, at 5:00 p.m. Eastern Time.

How can I participate in the Corcept Therapeutics conference call?

You can join the conference call by clicking the provided link or dialing the designated phone numbers.

What types of disorders is Corcept Therapeutics targeting with its compounds?

Corcept Therapeutics is targeting disorders such as Cushing's syndrome, various cancers, weight gain from antipsychotics, and liver disease.